Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 9/20 | 0.42 |
| ▸ | CTSS | P25774 | 4/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12523040 | 1.00 | CA2 (0.47) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL86157 | 0.85 | CA2 (0.53) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL272661 | 0.85 | CA2 (0.53) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL84553 | 0.85 | CA2 (0.53) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL23125479 | 0.85 | CA1 (0.46) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL22404435 | 0.84 | CA1 (0.49) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL16569009 | 0.84 | CA1 (0.49) | CA2CA1CA7CYP2D6CTSK | |
| Hydrochloric Acid SCHEMBL10594711 | 0.84 | CA2 (0.51) | CA2CA1CA7CYP2D6CTSK | |
| Hydrochloric Acid SCHEMBL29408471 | 0.84 | CA2 (0.51) | CA2CA1CA7CYP2D6CTSK | |
| Hydrochloric Acid SCHEMBL29197256 | 0.84 | CA2 (0.51) | CA2CA1CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160317508-A1 | Fused Amino Pyridines for the Treatment of Lung Cancer | CURIS INC (US) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160317508-A1 | Fused Amino Pyridines for the Treatment of Lung Cancer | IDH2, IDH1, SLC1A2 | CA2 1885/4885CA1 653/4885CA7 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.